The Australian Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Neuromyelitis Optica Spectrum Disorder (NMOSD) is previously known as Devic Syndrome, a rare and devastating, autoimmune, inflammatory disorder of the central nervous system (CNS) characterized by severe axonal damage, primarily to the optic nerve and the spinal cord, sudden and unpredictable relapses, also known as attacks. Each relapse results in stepwise accumulation of disability, including blindness, paralysis, bowel and bladder dysfunction and sometimes leads to premature death. Uncontrolled complement activation triggered by anti-AQP4 auto antibodies is a major underlying mechanism of the disease.
The lowest incidence and prevalence of NMOSD were found in Australia as 0.7/100,000 persons. There was prominent female predominance in adults. The incidence and prevalence peaked in middle-aged adults. Variations in prevalence and incidence have been described among different geographic areas and ethnicities. Current research indicates that neuromyelitis optica (NMO) patients have a 91% to 98% five-year survival rate. Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which are present in 50% of cases.
The expansion of the NMOSD market is attributed to emerging markets and large investments in research & development. The introduction of new therapeutics for the acute phase or prevention of Neuromyelitis Optica Spectrum Disorder presents a potential commercial potential.
The Neuromyelitis Optica Spectrum Disorder (NMOSD) market is majorly driven by the rise in incidence of Neuromyelitis Optica Spectrum Disorder (NMOSD). In addition, emergence of drugs used in the prevention of Neuromyelitis Optica Spectrum Disorder (NMOSD) and improvement in healthcare facilities are some of the impacting factors that drives the market growth.
Nevertheless, less trained expertise or technically skilled professionals coupled with high treatment cost significantly hinder the growth of this market.